Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies, and other serious diseases. Co.'s pipeline is built on the differentiated therapeutic potential of its primary product candidate, tovinontrine (IMR-687), which is an oral, small molecule inhibitor of phosphodiesterase-9. Tovinontrine is in Phase 2b clinical development for the treatment of sickle cell disease and ß-thalassemia. Co. is also developing IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2–related factor 2. We show 13 historical shares outstanding datapoints in our IMRA shares outstanding history coverage, used to compute IMRA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing IMRA market cap history over the course of time is important for investors
interested in comparing IMRA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of IMRA versus a peer is one thing; comparing
IMRA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like IMRA can fluctuate over the course of history.
With this page we aim to empower investors researching IMRA by allowing them to research the IMRA market cap history. |
Free IMRA Email Alerts:
Video: The Importance of Market Cap
